TRIPEP RAISES SEK 21 MILLION IN A PRIVATE PLACEMENT

TRIPEP RAISES SEK 21 MILLION IN A PRIVATE PLACEMENT The Board of Directors of Tripep AB (publ) has, by virtue of authorisation from the annual general meeting, adopted a resolution to carry out a private placement through which Tripep will raise approx SEK 21.25 million excluding issue costs. The transaction will be carried out through an issue of 1.4 million new shares and a sale of 1.1 million treasury shares. The shares are sold at a price of SEK 8.50 per share, equal to the average market price of shares in Tripep during the week preceding the resolution. In consultation with its financial advisor, the Irish stock broker firm NCB, Tripep will place the shares with a restricted circle of private investors. A company controlled by Tripep's chairman Rolf L. Nordström will guarantee the transaction in full in order to secure its successful accomplishment. The presently resolved financing reduces the need to obtain a secondary listing on the Alternative Investment Market (AIM) at the London Stock Exchange and the board of directors of Tripep has therefore resolved to shelve the plans on a secondary listing for the time being.   "It is positive that the finansing, by a comfortable margin, now is in place. This will take us through the whole phase I/II clinical study on HIV infected individuals with our candidate drug alphaHGA. We can now focus entirely on this study, which after the positive toxicology results just received is planned to start early next year", says Tripep's chairman Rolf L. Nordström. Please also see today's press release regarding the the positive outcome of the safety and toxicology studies on Tripep's anti-HIVdrug candidate alphaHGA. For more information, please contact: Rolf Nordström, Chairman, Tripep AB Tel: +44 20 7839 8686, mobile phone: +44 7776 137 400 E-mail: rolf.l.nordstrom@btinternet.com   Anders Vahlne, CEO and Head of Research, Tripep AB Tel: +46 35 31755, mobile phone: +46 709-28 05 28 E-mail: anders.vahlne@labmed.ki.se   Conor McCarthy, NCB, Dublin, Ireland Tel: +353 1 611 5989, mobile phone: +353 87 290 0409 E-mail: conor.mccarthy@ncb.ie   Lisa Baderoon, Rebecca Skye Dietrich Buchanan Communications Tel: + 44 20 7466 5000, mobile phone: +44 7721 413 496 E-mail: lisab@buchanan.uk.com   Notes to Editors:   Tripep AB is a Swedish biotechnology research company that develops and commercialises candidate drugs based on patented technologies. Its main focuses are:   - research and development of an HIV-inhibiting drug, - preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and Hepatitis C, and - the RAS ®  technology platform.   For more details of the company's technologies, please refer to the company's web site at www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/10/12/20041012BIT22220/wkr0001.pdf

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Subscribe

Documents & Links